Cougar Biotechnology: Stalking Prostate Cancer Cougar Biotechnology (CGRB) is a publicly traded company focused on developing novel treatments for cancer.The company is developing CB7630 (Abiraterone Acetate), a small molecule for the treatment of hormone refractory prostate cancer ...
Packaging Market Weekly Wrap - P&G to Procter & Gamble is allowing another company access to its packaging technologies for the first time.Food manufacturer ConAgra will get access to its industry-leading packaging and design skills in one of the most ambitious...
Cancer researcher hopes to mitigate chemo damage SACRAMENTO, Calif.Chemotherapy helped cure Melinda Duttons breast cancer, but it left her with a badly damaged heart.
Bruce Ogden, who survived prostate cancer that had spread to his bones, lives with feminizing changes to his body from...
EU firms urge ban on drug repackaging PARIS Drugmakers called yesterday for a ban on the repackaging of medicines within the European Union in order to stamp out the growing threat of counterfeits.It is absolutely imperative, if we are going to try and protect consumers from...
Reportbuyer: Parallel Trade of Pharmaceutical Tops European Commission Agenda, says New Report Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report analysing pharmaceutical supply chain strategies.'Pharmaceutical Supply Chain Strategies', which is available at http://www...
Reportbuyer: Parallel Trade of Pharmaceutical Tops European Commission Agenda, says New Report Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report analysing pharmaceutical supply chain strategies.'Pharmaceutical Supply Chain Strategies', which is available at http://www...
Generic Erosion Will Constrain Prostate Cancer Drug Market, Resulting in Annual Growth of Less Than 2 Percent However, Annual Market Growth Will Increase to 4.5 Percent from 2012 to 2017 Due to Emergence of Premium-Priced Drugs, According to a New Report from Decision Resources WALTHAM, Mass., June 03, 2008 /PRNewswire/ -- Decision Resources, one of...
Latest news from Datamonitor Drug distribution restricted as manufacturers attempt to guard supply chain Ideally, drug supply should be a simple and transparent chain that connects the manufacturer and patient in as few steps as possible.However, in practice, this is...
Cancer researcher hopes to mitigate chemo damage SACRAMENTO, Calif.-- Chemotherapy helped cure Melinda Dutton's breast cancer, but it left her with a badly damaged heart.
Bruce Ogden, who survived prostate cancer that had spread to his bones, lives with feminizing changes to his body...
Latest news from Datamonitor Drug distribution restricted as manufacturers attempt to guard supply chain Ideally, drug supply should be a simple and transparent chain that connects the manufacturer and patient in as few steps as possible.However, in practice, this is...
Generic Erosion Will Constrain Prostate Cancer Drug Market, Resulting in Annual Growth of Less Than 2 Percent WALTHAM, Mass., June 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion will significantly constrain the prostate cancer drug...
Generic Erosion Will Constrain Prostate Cancer Drug Market, Resulting in Annual Growth of Less Than 2 Percent However, Annual Market Growth Will Increase to 4.5 Percent from 2012 to 2017 Due to Emergence of Premium-Priced Drugs, According to a New Report from Decision Resources WALTHAM, Mass., June 3 /PRNewswire/ -- Decision Resources, one of the...
Generic Erosion Will Constrain Prostate Cancer Drug Market, Resulting in Annual Growth of Less Than 2 Percent However, Annual Market Growth Will Increase to 4.5 Percent from 2012 to 2017 Due to Emergence of Premium-Priced Drugs, According to a New Report from Decision Resources WALTHAM, Mass., June 3 WALTHAM, Mass., June 3 /PRNewswire/ -- Decision...
Generic Erosion Will Constrain Prostate Cancer Drug Market, Resulting in Annual Growth of Less Than 2 Percent WALTHAM, Mass., June 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion will significantly constrain the prostate cancer drug...
Generic Erosion Will Constrain Prostate Cancer Drug Market, Resulting in Annual Growth of Less Than 2 Percent WALTHAM, Mass., June 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion will significantly constrain the prostate cancer drug...
There are no Less than 280 Therapeutics Targeting Prostate Cancer Today Cancer of the prostate is the second most frequently diagnosed cancer in men in the US.The prostate cancer market is reaching maturity, and major players' sales have been eroded by the launch of various LHRH agonist depot formulations.
There are no Less than 280 Therapeutics Targeting Prostate Cancer Today DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/reportinfo.asp?report_id=367282) has announced the addition of Prostate Cancer: Drug Pipeline Update 2008 to their offering.Cancer of the prostate...
